QQ客服 官方微博 反馈留言

	RECORD-4 multicenter phase II trial of second-line everolimus (EVE) in patients (pts) with metastatic renal cell carcinoma (mRCC): Anti-VEGF cohort subanalysis.
	Cosgriff, Thomas; Yang, Lin; Alyasova, Anna; Ye, Dingwei; Karpenko, Andrey; Li, Hanzhong; Alekseev, Boris; Xie, Li-ping; Kowalyszyn, Ruben Dario; Karyakin, Oleg
	2016
卷号	34期号:2
ISSN号	0732-183X
URL标识	查看原文
收录类别	SCIE
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/6374252
专题	中国医学科学院 北京协和医学院
推荐引用方式 GB/T 7714	Cosgriff, Thomas,Yang, Lin,Alyasova, Anna,et al. RECORD-4 multicenter phase II trial of second-line everolimus (EVE) in patients (pts) with metastatic renal cell carcinoma (mRCC): Anti-VEGF cohort subanalysis.[J],2016,34(2).
APA	Cosgriff, Thomas.,Yang, Lin.,Alyasova, Anna.,Ye, Dingwei.,Karpenko, Andrey.,...&Motzer, Robert J..(2016).RECORD-4 multicenter phase II trial of second-line everolimus (EVE) in patients (pts) with metastatic renal cell carcinoma (mRCC): Anti-VEGF cohort subanalysis..,34(2).
MLA	Cosgriff, Thomas,et al."RECORD-4 multicenter phase II trial of second-line everolimus (EVE) in patients (pts) with metastatic renal cell carcinoma (mRCC): Anti-VEGF cohort subanalysis.".34.2(2016).

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。